Anat Naschitz Net Worth

The estimated Net Worth of Anat Naschitz is at least $22.8 Миллион dollars as of 21 September 2020. Ms. Naschitz owns over 275,000 units of 89bio Inc stock worth over $15,122,887 and over the last 5 years she sold ETNB stock worth over $7,700,000. In addition, she makes $8,334 as Independent Director at 89bio Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Naschitz ETNB stock SEC Form 4 insiders trading

Anat has made over 2 trades of the 89bio Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently she sold 275,000 units of ETNB stock worth $7,700,000 on 21 September 2020.

The largest trade she's ever made was buying 837,500 units of 89bio Inc stock on 11 November 2019 worth over $13,400,000. On average, Anat trades about 222,500 units every 63 days since 2019. As of 21 September 2020 she still owns at least 1,864,721 units of 89bio Inc stock.

You can see the complete history of Ms. Naschitz stock trades at the bottom of the page.

Anat Naschitz biography

Anat Naschitz serves as Independent Director of the Company. Ms. Naschitz has served as a member of our Board since January 2018, and played a key role in creating 89bio Ltd. as a spinout from a pharmaceutical company. Ms. Naschitz has served as Managing Director at OrbiMed, a global healthcare investment firm, since January 2010. Ms. Naschitz has over 20 years of healthcare experience. Previously, Ms. Naschitz created, invested in and advised healthcare companies across stages and substance. She was an Associate Partner with McKinsey in London from 1995 to 2002, where she managed strategy, company formation through spinouts and mergers and acquisitions projects for senior management of the world’s leading pharmaceutical and biotechnology companies. Subsequently, Ms. Naschitz was a Principal at Apax Partners, where she invested in healthcare companies. She currently serves on the boards of biotech and digital health companies and served on the board of Medigus Ltd., a medical device company, from March 2013 to June 2017.

What is the salary of Anat Naschitz?

As the Independent Director of 89bio Inc, the total compensation of Anat Naschitz at 89bio Inc is $8,334. There are 9 executives at 89bio Inc getting paid more, with Rohan Palekar having the highest compensation of $1,022,610.

How old is Anat Naschitz?

Anat Naschitz is 52, she's been the Independent Director of 89bio Inc since 2018. There are 11 older and 4 younger executives at 89bio Inc. The oldest executive at 89bio Inc is Michael Hayden, 68, who is the Independent Director.

What's Anat Naschitz's mailing address?

Anat's mailing address filed with the SEC is C/O 89BIO, INC., 142 SANSOME STREET, 2ND FLOOR, SAN FRANCISCO, CA, 94104.

Insiders trading at 89bio Inc

Over the last 5 years, insiders at 89bio Inc have traded over $17,267,666 worth of 89bio Inc stock and bought 14,519,952 units worth $208,678,684 . The most active insiders traders include Capital Management, L.P.Ra ..., Capital Management, L.P.Ra ... и Advisors Llc Orbi Med Capit.... On average, 89bio Inc executives and independent directors trade stock every 28 days with the average trade being worth of $2,197,340. The most recent stock trade was executed by Rohan Palekar on 1 April 2024, trading 52,718 units of ETNB stock currently worth $575,153.

What does 89bio Inc do?

89bio, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. its lead product candidate is bio89-100, a glycopegylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. the company also intends to develop bio89-100 for the treatment of severe hypertriglyceridemia. 89bio, inc. was founded in 2018 and is based in san francisco, california.

Complete history of Ms. Naschitz stock trades at 89bio Inc

89bio Inc executives and stock owners

89bio Inc executives and other stock owners filed with the SEC include:

• Rohan Palekar,
  Chief Executive Officer, Director
• Rohan Palekar,
  CEO & Director
• Hank Mansbach,
  Chief Medical Officer
• Dr. Harry Mansbach M.D.,
  Chief Medical Officer
• Dr. Hank Mansbach M.D.,
  Chief Medical Officer
• Quoc Le-Nguyen,
  Chief Technical Operations Officer and Head of Quality
• Quoc Le-Nguyen,
  Chief Technical Operations Officer & Head of Quality
• Ram Waisbourd,
  Chief Operating Officer and Chief Business Officer
• Michael Hayden,
  Independent Director
• Anat Naschitz,
  Independent Director
• Gregory Grunberg,
  Independent Director
• Derek DiRocco,
  Independent Director
• Ryan Martins,
  Chief Financial Officer
• Steven Altschuler,
  Independent Chairman of the Board of Director
• Yun Bai,
  VP & Head of CMC
• Amanda Hill,
  VP of People & Culture
• Melissa Abel,
  VP of Commercial Strategy & Communication
• Shiva K. Natarajan,
  VP of Fin. & Principal Accounting Officer
• Ram Waisbourd,
  COO & Chief Bus. Officer
• Ryan Stephen Martins,
  Chief Financial Officer
• Charles Mc Wherter,
  
• Tomer Pontifax (Israel) V, ...,
  
• Capital Management, L.P.Ra ...,
  
• Advisors Llc Orbi Med Capit...,
  
• Capital Partners Iii, Llc L...,
  
• Kathleen Laporte,
  
• Edward Morrow Iii Atkinson,
  
• Capital Management, L.P.Ra ...,
  
• Harry H Mansbach,
  Chief Medical Officer
• Lota S. Zoth,
  
• Martin Babler,
  
• Francis Willard Sarena,
  Chief Operating Officer